Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, J. | - |
dc.contributor.author | Lee, E.H. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Choi, B.M. | - |
dc.contributor.author | Hong, Y.S. | - |
dc.date.accessioned | 2021-09-03T14:07:40Z | - |
dc.date.available | 2021-09-03T14:07:40Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1738-1061 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/86129 | - |
dc.description.abstract | Purpose: Plasma level of B-type natriuretic peptide (BNP), an emerging, sensitive, and specific biomarker of hemodynamically significant patent ductus arteriosus (PDA), rapidly decreases in infants receiving cyclooxygenase inhibitors for ductal closure. We investigated the usefulness of serial BNP measurement as a guide for individual identification of early constrictive responses to ibuprofen in preterm infants with symptomatic PDA (sPDA). Methods: Before March 2010, the standard course of pharmacological treatment was initiated with indomethacin (or ibuprofen) and routinely followed by 2 additional doses at intervals of 24 hours. After April 2010, individualized pharmacological treatment was used, starting with the first dose of ibuprofen and withholding additional ibuprofen doses if the BNP concentration was <600 pg/mL and clinical symptoms of PDA improved. Results: The BNP-guided group received significantly fewer doses of ibuprofen than the standard group did during the first course of treatment and the entire study period. The need for further doses of cyclooxygenase inhibitors and for surgical ligation was not significantly different between the 2 groups. No significant differences were seen in clinical outcomes and/or complications related to sPDA and/or pharmacological treatment. Conclusion: Individualized BNP-guided pharmacological treatment may be used clinically to avoid unnecessary doses of cyclooxygenase inhibitors without increasing the ductal closure failure and the short-term morbidity related to sPDA. © 2017 by The Korean Pediatric Society. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Korean Pediatric Society | - |
dc.subject | brain natriuretic peptide | - |
dc.subject | ibuprofen | - |
dc.subject | indometacin | - |
dc.subject | surfactant | - |
dc.subject | Apgar score | - |
dc.subject | Article | - |
dc.subject | artificial ventilation | - |
dc.subject | clinical article | - |
dc.subject | clinical outcome | - |
dc.subject | concentration (parameters) | - |
dc.subject | controlled study | - |
dc.subject | creatinine blood level | - |
dc.subject | echocardiography | - |
dc.subject | female | - |
dc.subject | hospitalization | - |
dc.subject | human | - |
dc.subject | immunofluorescence test | - |
dc.subject | male | - |
dc.subject | newborn | - |
dc.subject | observational study | - |
dc.subject | patent ductus arteriosus | - |
dc.subject | patient safety | - |
dc.subject | personalized medicine | - |
dc.subject | preeclampsia | - |
dc.subject | prematurity | - |
dc.title | Individualized ibuprofen treatment using serial B-type natriuretic peptide measurement for symptomatic patent ductus arteriosus in very preterm infants | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, B.M. | - |
dc.contributor.affiliatedAuthor | Hong, Y.S. | - |
dc.identifier.doi | 10.3345/kjp.2017.60.6.175 | - |
dc.identifier.scopusid | 2-s2.0-85021066937 | - |
dc.identifier.bibliographicCitation | Korean Journal of Pediatrics, v.60, no.6, pp.175 - 180 | - |
dc.relation.isPartOf | Korean Journal of Pediatrics | - |
dc.citation.title | Korean Journal of Pediatrics | - |
dc.citation.volume | 60 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 175 | - |
dc.citation.endPage | 180 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002230797 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | brain natriuretic peptide | - |
dc.subject.keywordPlus | ibuprofen | - |
dc.subject.keywordPlus | indometacin | - |
dc.subject.keywordPlus | surfactant | - |
dc.subject.keywordPlus | Apgar score | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | artificial ventilation | - |
dc.subject.keywordPlus | clinical article | - |
dc.subject.keywordPlus | clinical outcome | - |
dc.subject.keywordPlus | concentration (parameters) | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | creatinine blood level | - |
dc.subject.keywordPlus | echocardiography | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | hospitalization | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | immunofluorescence test | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | newborn | - |
dc.subject.keywordPlus | observational study | - |
dc.subject.keywordPlus | patent ductus arteriosus | - |
dc.subject.keywordPlus | patient safety | - |
dc.subject.keywordPlus | personalized medicine | - |
dc.subject.keywordPlus | preeclampsia | - |
dc.subject.keywordPlus | prematurity | - |
dc.subject.keywordAuthor | B-type natriuretic peptide | - |
dc.subject.keywordAuthor | Ibuprofen | - |
dc.subject.keywordAuthor | Patent ductus arteriosus | - |
dc.subject.keywordAuthor | Preterm infant | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.